| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8485697 | Vaccine | 2018 | 7 Pages |
Abstract
While government financing has increased, some operating costs continue to be provided from revenue generated by sales of Category 2 (private-sector) vaccines to families. China could benefit from bringing new and underutilized vaccines into the EPI system based on evidence that includes routine immunization vaccine and operations costs.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Wenzhou Yu, Ming Lu, Huaqing Wang, Lance Rodewald, Saisai Ji, Chao Ma, Yixing Li, Jingshan Zheng, Yifan Song, Miao Wang, Yamin Wang, Dan Wu, Lei Cao, Chunxiang Fan, Xuan Zhang, Yanmin Liu,